Delavirdine (BioDeep_00000006383)

human metabolite blood metabolite Chemicals and Drugs Volatile Flavor Compounds

代谢物信息卡片

1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulphonyl)amino)-1H-indol-2-yl)carbonyl)piperazine

化学式: C22H28N6O3S (456.19434980000005)
中文名称: 地拉韦啶
谱图信息: 最多检出来源 Homo sapiens(blood) 2.06%

分子结构信息

SMILES: CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
InChI: InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3

描述信息

Delavirdine is only found in individuals that have used or taken this drug. It is a potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. [PubChem]Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzymes catalytic site.
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AG - Non-nucleoside reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent

同义名列表

17 个代谢物同义名

1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulphonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; (N-[2-[4-[3-(1-Methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulphonamide); (N-[2-[4-[3-(1-Methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); N-[2-(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazine-1-carbonyl)-1H-indol-5-yl]methanesulfonamide; 2-(4-(5-Methanesulphonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine; N-{2-[4-(3-isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulphonamide; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine; N-{2-[4-(3-isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; N-(2-(1-(3-(Isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulphonamide; N-(2-(1-(3-(Isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; Pfizer brand OF delavirdine mesilate; Mesylate, delavirdine; DELAVIRDINE MESYLATE; Delavirdine; Rescriptor; Delavirdine

数据库引用编号

17 个数据库交叉引用编号

ChEBI: CHEBI:119573
KEGG: C06941
KEGGdrug: D07782
PubChem: 5625
HMDB: HMDB0014843
Metlin: METLIN66564
DrugBank: DB00705
ChEMBL: CHEMBL593
Wikipedia: Delavirdine
MeSH: Delavirdine
chemspider: 5423
CAS: 136817-59-9
PMhub: MS000019414
PubChem: 9156
PDB-CCD: SPP
NIKKAJI: J571.558J
KNApSAcK: 119573

分类词条

Phenylalanine and derivatives

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 - Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

文献列表

Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
Venkateswaran Shekar, Abhi Shah, Mohammad Shadid, Jing-Tao Wu, Jayaprakasam Bolleddula, Swapan Chowdhury. An accelerated background subtraction algorithm for processing high-resolution MS data and its application to metabolite identification. Bioanalysis. 2016 Aug; 8(16):1693-707. doi: 10.4155/bio-2016-0101. [PMID: 27460980]
Raveen Parboosing, Glenn E M Maguire, Patrick Govender, Hendrik G Kruger. Nanotechnology and the treatment of HIV infection. Viruses. 2012 04; 4(4):488-520. doi: 10.3390/v4040488. [PMID: 22590683]
Yung-Chih Kuo, Chiu-Yen Chung. Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids and surfaces. B, Biointerfaces. 2011 Dec; 88(2):682-90. doi: 10.1016/j.colsurfb.2011.07.060. [PMID: 21865017]
Luke C Swenson, Graham Pollock, Brian Wynhoven, Theresa Mo, Winnie Dong, Robert S Hogg, Julio S G Montaner, P Richard Harrigan. 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice. PloS one. 2011 Feb; 6(2):e17402. doi: 10.1371/journal.pone.0017402. [PMID: 21390218]
Santiago Avila-Ríos, Claudia García-Morales, Daniela Garrido-Rodríguez, Christopher E Ormsby, Ramón Hernández-Juan, Jaime Andrade-Villanueva, Luz A González-Hernández, Indiana Torres-Escobar, Samuel Navarro-Álvarez, Gustavo Reyes-Terán. National prevalence and trends of HIV transmitted drug resistance in Mexico. PloS one. 2011; 6(11):e27812. doi: 10.1371/journal.pone.0027812. [PMID: 22110765]
Rama Mallipeddi, Lisa Cencia Rohan. Progress in antiretroviral drug delivery using nanotechnology. International journal of nanomedicine. 2010 Aug; 5(?):533-47. doi: 10.2147/ijn.s7681. [PMID: 20957115]
Markus Fridén, Susanne Winiwarter, Gunilla Jerndal, Ola Bengtsson, Hong Wan, Ulf Bredberg, Margareta Hammarlund-Udenaes, Madeleine Antonsson. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. Journal of medicinal chemistry. 2009 Oct; 52(20):6233-43. doi: 10.1021/jm901036q. [PMID: 19764786]
Valerio Tozzi, Pietro Balestra, Maria Flora Salvatori, Chrysoula Vlassi, Giuseppina Liuzzi, Maria Letizia Giancola, Marinella Giulianelli, Pasquale Narciso, Andrea Antinori. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. Journal of acquired immune deficiency syndromes (1999). 2009 Sep; 52(1):56-63. doi: 10.1097/qai.0b013e3181af83d6. [PMID: 19731418]
David E Moody, Yan Chang, Wei Huang, Elinore F McCance-Katz. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic & clinical pharmacology & toxicology. 2009 Sep; 105(3):211-5. doi: 10.1111/j.1742-7843.2009.00432.x. [PMID: 19500085]
Carmen D Zorrilla, Vivian Tamayo-Agrait. Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. HIV/AIDS (Auckland, N.Z.). 2009; 1(?):41-53. doi: 10.2147/hiv.s6326. [PMID: 22096378]
Jean-Marie Poirier, Pascal Robidou, Patrice Jaillon. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 May; 867(2):277-81. doi: 10.1016/j.jchromb.2008.03.026. [PMID: 18434263]
Shu-Feng Zhou. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current drug metabolism. 2008 May; 9(4):310-22. doi: 10.2174/138920008784220664. [PMID: 18473749]
Subroto Acharjee, Francine K Welty. Atorvastatin and cardiovascular risk in the elderly--patient considerations. Clinical interventions in aging. 2008; 3(2):299-314. doi: 10.2147/cia.s2442. [PMID: 18686752]
Xiaoyan Zhang, Shenwei Li, Xinping Li, Xinxu Li, Jianqing Xu, Dongliang Li, Yuhua Ruan, Hui Xing, Xiaoxi Zhang, Yiming Shao. Characterization of HIV-1 subtypes and viral antiretroviral drug resistance in men who have sex with men in Beijing, China. AIDS (London, England). 2007 Dec; 21 Suppl 8(?):S59-65. doi: 10.1097/01.aids.0000304698.47261.b1. [PMID: 18172393]
Shu-Feng Zhou, Charlie Changli Xue, Xue-Qing Yu, Chunguang Li, Guangji Wang. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic drug monitoring. 2007 Dec; 29(6):687-710. doi: 10.1097/ftd.0b013e31815c16f5. [PMID: 18043468]
Yung-Chih Kuo, Fu-Lung Su. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. International journal of pharmaceutics. 2007 Aug; 340(1-2):143-52. doi: 10.1016/j.ijpharm.2007.03.012. [PMID: 17418986]
Akiko Watanabe, Koichi Nakamura, Noriko Okudaira, Osamu Okazaki, Ken-ichi Sudo. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug metabolism and disposition: the biological fate of chemicals. 2007 Jul; 35(7):1232-8. doi: 10.1124/dmd.107.015016. [PMID: 17392390]
Anne-Kathrin Gehrig, Gerd Mikus, Walter E Haefeli, Jürgen Burhenne. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. Rapid communications in mass spectrometry : RCM. 2007; 21(16):2704-16. doi: 10.1002/rcm.3138. [PMID: 17639576]
Gillian Hales, Chris Birch, Suzanne Crowe, Cassy Workman, Jennifer F Hoy, Matthew G Law, Anthony D Kelleher, Douglas Lincoln, Sean Emery. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. PLoS clinical trials. 2006 Jul; 1(3):e18. doi: 10.1371/journal.pctr.0010018. [PMID: 16878178]
Kok Keng Tee, Adeeba Kamarulzaman, Kee Peng Ng. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. AIDS research and human retroviruses. 2006 Feb; 22(2):121-4. doi: 10.1089/aid.2006.22.121. [PMID: 16478392]
M Escoto-Delgadillo, E Vázquez-Valls, M Ramírez-Rodríguez, A Corona-Nakamura, G Amaya-Tapia, N Quintero-Pérez, A Panduro-Cerda, B M Torres-Mendoza. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico. HIV medicine. 2005 Nov; 6(6):403-9. doi: 10.1111/j.1468-1293.2005.00326.x. [PMID: 16268822]
Patrick F Smith, Robert Dicenzo, Alan Forrest, Mark Shelton, Gerald Friedland, Michael Para, Richard Pollard, Margaret Fischl, Robin DiFrancesco, Gene D Morse. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clinical pharmacokinetics. 2005; 44(1):99-109. doi: 10.2165/00003088-200544010-00004. [PMID: 15634033]
Edouard Tuaillon, Marie Gueudin, Véronique Lemée, Isabelle Gueit, Pierre Roques, Gary E Corrigan, Jean-Christophe Plantier, François Simon, Joséphine Braun. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. Journal of acquired immune deficiency syndromes (1999). 2004 Dec; 37(5):1543-9. doi: 10.1097/00126334-200412150-00001. [PMID: 15577405]
Koen Andries, Hilde Azijn, Theo Thielemans, Donald Ludovici, Michael Kukla, Jan Heeres, Paul Janssen, Bart De Corte, Johan Vingerhoets, Rudi Pauwels, Marie-Pierre de Béthune. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrobial agents and chemotherapy. 2004 Dec; 48(12):4680-6. doi: 10.1128/aac.48.12.4680-4686.2004. [PMID: 15561844]
Kurt Vermeire, Katrien Princen, Sigrid Hatse, Erik De Clercq, Kaka Dey, Thomas W Bell, Dominique Schols. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS (London, England). 2004 Nov; 18(16):2115-25. doi: 10.1097/00002030-200411050-00003. [PMID: 15577644]
Erik J Uhlmann, Pablo Tebas, Gregory A Storch, William G Powderly, Yolanda S Lie, Jeannette M Whitcomb, Nicholas S Hellmann, Max Q Arens. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2004 Nov; 31(3):198-203. doi: 10.1016/j.jcv.2004.03.012. [PMID: 15465412]
Wolfgang Egge-Jacobsen, Matthias Unger, Claus U Niemann, Muhammad Baluom, Sumiko Hirai, Leslie Z Benet, Uwe Christians. Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Therapeutic drug monitoring. 2004 Oct; 26(5):546-62. doi: 10.1097/00007691-200410000-00014. [PMID: 15385839]
Naser L Rezk, Richard R Tidwell, Angela D M Kashuba. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Jun; 805(2):241-7. doi: 10.1016/j.jchromb.2004.03.002. [PMID: 15135096]
Quyet Chien Nguyen, Van Hung Nguyen, Bernard D Santarsiero, Andrew D Mesecar, Manh Cuon Nguyen, D Doel Soejarto, John M Pezzuto, Harry H S Fong, Ghee T Tan. New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. Journal of natural products. 2004 Jun; 67(6):994-8. doi: 10.1021/np030469i. [PMID: 15217281]
N Gianotti, E Boeri, M Maillard, G Serra, D Ratti, G Gallotta, D Vacchini, Y Tremolada, A Castagna. In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results. The new microbiologica. 2004 Apr; 27(2 Suppl 1):111-7. doi: NULL. [PMID: 15646073]
Mark Mirochnick, Edmund Capparelli. Pharmacokinetics of antiretrovirals in pregnant women. Clinical pharmacokinetics. 2004; 43(15):1071-87. doi: 10.2165/00003088-200443150-00002. [PMID: 15568888]
S G O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, S Milosavljev, C Huber, R Capdeville, T Fischer. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British journal of cancer. 2003 Nov; 89(10):1855-9. doi: 10.1038/sj.bjc.6601152. [PMID: 14612892]
P Richard Harrigan, Kurt Hertogs, Werner Verbiest, Brendan Larder, Benita Yip, Zabrina L Brumme, Christopher Alexander, Jessica Tilley, Michael V O'Shaughnessy, Julio S G Montaner. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Antiviral therapy. 2003 Oct; 8(5):395-402. doi: NULL. [PMID: 14640386]
Xing-Wu Shao, Anders Malmsten, Johan Lennerstrand, Anders Sönnerborg, Torsten Unge, J Simon Gronowitz, Clas F Källander. Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing. AIDS (London, England). 2003 Jul; 17(10):1463-71. doi: 10.1097/00002030-200307040-00007. [PMID: 12824784]
Mark J Shelton, Ross G Hewitt, John Adams, Andrew Della-Coletta, Steven Cox, Gene D Morse. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrobial agents and chemotherapy. 2003 May; 47(5):1694-9. doi: 10.1128/aac.47.5.1694-1699.2003. [PMID: 12709342]
Michele L Turner, Kedria Reed-Walker, Jennifer R King, Edward P Acosta. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Feb; 784(2):331-41. doi: 10.1016/s1570-0232(02)00822-x. [PMID: 12505781]
Gene D Morse, Margaret A Fischl, Mark J Shelton, Steve R Cox, Leslie Thompson, Andrew A Della-Coletta, William W Freimuth. Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection. Clinical drug investigation. 2003; 23(4):255-61. doi: 10.2165/00044011-200323040-00005. [PMID: 17535038]
Gene D Morse, Susan E Cohn, Mark J Shelton, Carol Greisberger, Steven R Cox, Andrew A Della-Coletta, William W Freimuth, Richard C Reichman. Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients. Clinical drug investigation. 2003; 23(5):323-8. doi: 10.2165/00044011-200323050-00002. [PMID: 17535044]
Carme Vidal, Mireia Arnedo, Felipe Garcia, Gabriel Mestre, Montserrat Plana, Anna Cruceta, Alicia Capon, Teresa Gallart, José M Miro, Tomas Pumarola, José M Gatell. Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. Antiviral therapy. 2002 Dec; 7(4):283-7. doi: NULL. [PMID: 12553483]
Jeannette M Whitcomb, Wei Huang, Kay Limoli, Ellen Paxinos, Terri Wrin, Gail Skowron, Steven G Deeks, Michael Bates, Nicholas S Hellmann, Christos J Petropoulos. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS (London, England). 2002 Oct; 16(15):F41-7. doi: 10.1097/00002030-200210180-00002. [PMID: 12370521]
Afsoon D Roberts, Angelike P Liappis, Chris Chinn, David M Parenti, Richard A Muesing, Suzanne Z Schuck, Judy Hsia, Gary L Simon. Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy. AIDS (London, England). 2002 Sep; 16(13):1829-30. doi: 10.1097/00002030-200209060-00018. [PMID: 12218397]
Naser L Rezk, Richard R Tidwell, Angela D M Kashuba. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Jul; 774(1):79-88. doi: 10.1016/s1570-0232(02)00210-6. [PMID: 12052725]
Christopher K Finch, Cary R Chrisman, Anne M Baciewicz, Timothy H Self. Rifampin and rifabutin drug interactions: an update. Archives of internal medicine. 2002 May; 162(9):985-92. doi: 10.1001/archinte.162.9.985. [PMID: 11996607]
Jose G Castro, Luis Gutierrez. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. The American journal of medicine. 2002 Apr; 112(6):505. doi: 10.1016/s0002-9343(01)01135-4. [PMID: 11959068]
Ching-Ling Cheng, Chen-Hsi Chou, Oliver Yoa-Pu Hu. Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Apr; 769(2):297-303. doi: 10.1016/s1570-0232(02)00015-6. [PMID: 11996495]
Daniel S Engeler, Hubert John, Katharina M Rentsch, Christian Ruef, Daniel Oertle, Stefan Suter. Nelfinavir urinary stones. The Journal of urology. 2002 Mar; 167(3):1384-5. doi: NULL. [PMID: 11832739]
G Maga, A Ramunno, V Nacci, G A Locatelli, S Spadari, I Fiorini, F Baldanti, S Paolucci, M Zavattoni, A Bergamini, B Galletti, S Muck, U Hubscher, G Giorgi, G Guiso, S Caccia, G Campiani. The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors. The Journal of biological chemistry. 2001 Nov; 276(48):44653-62. doi: 10.1074/jbc.m106702200. [PMID: 11572864]
P D Walzer, A Ashbaugh, M Collins, M T Cushion. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. The Journal of infectious diseases. 2001 Nov; 184(10):1355-7. doi: 10.1086/323991. [PMID: 11679930]
T Middleton, D Smith, B Larder, M Law, C Birch. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. HIV clinical trials. 2001 Nov; 2(6):445-52. doi: 10.1310/yhge-07y8-t3xf-f6vt. [PMID: 11742431]
E Toma, D Devost, N Chow Lan, P V Bhat. HIV-protease inhibitors alter retinoic acid synthesis. AIDS (London, England). 2001 Oct; 15(15):1979-84. doi: 10.1097/00002030-200110190-00010. [PMID: 11600826]
P Villani, M Feroggio, L Gianelli, A Bartoli, M Montagna, R Maserati, M B Regazzi. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. Therapeutic drug monitoring. 2001 Aug; 23(4):380-8. doi: 10.1097/00007691-200108000-00010. [PMID: 11477320]
L Bacheler, S Jeffrey, G Hanna, R D'Aquila, L Wallace, K Logue, B Cordova, K Hertogs, B Larder, R Buckery, D Baker, K Gallagher, H Scarnati, R Tritch, C Rizzo. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. Journal of virology. 2001 Jun; 75(11):4999-5008. doi: 10.1128/jvi.75.11.4999-5008.2001. [PMID: 11333879]
M Grodesky, E P Acosta, N Fujita, S Mason, J G Gerber. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations. HIV clinical trials. 2001 May; 2(3):193-9. doi: 10.1310/lj7m-82qx-5qjj-1r6r. [PMID: 11590527]
C Adjé, R Cheingsong, T H Roels, C Maurice, G Djomand, W Verbiest, K Hertogs, B Larder, B Monga, M Peeters, S Eholie, E Bissagene, M Coulibaly, R Respess, S Z Wiktor, T Chorba, J N Nkengasong. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. Journal of acquired immune deficiency syndromes (1999). 2001 Apr; 26(5):501-6. doi: 10.1097/00126334-200104150-00018. [PMID: 11391173]
V A Simon, M D Thiam, L C Lipford. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. Journal of chromatography. A. 2001 Apr; 913(1-2):447-53. doi: 10.1016/s0021-9673(00)01092-x. [PMID: 11355843]
D Smith, G Hales, N Roth, M Law, J Ray, J Druett, J Mitchell, G Mills, N Doong, R Franklin. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV clinical trials. 2001 Mar; 2(2):97-107. doi: 10.1310/cfyj-26jf-vvru-7an8. [PMID: 11590517]
J Gill, J Feinberg. Saquinavir soft gelatin capsule: a comparative safety review. Drug safety. 2001; 24(3):223-32. doi: 10.2165/00002018-200124030-00005. [PMID: 11347724]
J Q Tran, J G Gerber, B M Kerr. Delavirdine: clinical pharmacokinetics and drug interactions. Clinical pharmacokinetics. 2001; 40(3):207-26. doi: 10.2165/00003088-200140030-00005. [PMID: 11327199]
L J Scott, C M Perry. Delavirdine: a review of its use in HIV infection. Drugs. 2000 Dec; 60(6):1411-44. doi: 10.2165/00003495-200060060-00013. [PMID: 11152019]
D R Kuritzkes, R L Bassett, V A Johnson, I C Marschner, J J Eron, J P Sommadossi, E P Acosta, R L Murphy, K Fife, K Wood, D Bell, A Martinez, C B Pettinelli. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. AIDS (London, England). 2000 Jul; 14(11):1553-61. doi: 10.1097/00002030-200007280-00011. [PMID: 10983642]
M Gangar, G Arias, J G O'Brien, C A Kemper. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. The Annals of pharmacotherapy. 2000 Jul; 34(7-8):839-42. doi: 10.1345/aph.19258. [PMID: 10928391]
B Conway. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2000 Jun; 30 Suppl 2(?):S130-4. doi: 10.1086/313850. [PMID: 10860897]
A Frostell-Karlsson, A Remaeus, H Roos, K Andersson, P Borg, M Hämäläinen, R Karlsson. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. Journal of medicinal chemistry. 2000 May; 43(10):1986-92. doi: 10.1021/jm991174y. [PMID: 10821711]
J W Corbett, S S Ko, J D Rodgers, L A Gearhart, N A Magnus, L T Bacheler, S Diamond, S Jeffrey, R M Klabe, B C Cordova, S Garber, K Logue, G L Trainor, P S Anderson, S K Erickson-Viitanen. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. Journal of medicinal chemistry. 2000 May; 43(10):2019-30. doi: 10.1021/jm990580e. [PMID: 10821714]
J L Casado, K Hertogs, L Ruiz, F Dronda, A Van Cauwenberge, A Arnó, I Garcia-Arata, S Bloor, A Bonjoch, J Blazquez, B Clotet, B Larder. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS (London, England). 2000 Jan; 14(2):F1-7. doi: 10.1097/00002030-200001280-00001. [PMID: 10708276]
J W Corbett, S S Ko, J D Rodgers, S Jeffrey, L T Bacheler, R M Klabe, S Diamond, C M Lai, S R Rabel, J A Saye, S P Adams, G L Trainor, P S Anderson, S K Erickson-Viitanen. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrobial agents and chemotherapy. 1999 Dec; 43(12):2893-7. doi: 10.1128/aac.43.12.2893. [PMID: 10582878]
B Clotet. Efavirenz: resistance and cross-resistance. International journal of clinical practice. Supplement. 1999 Jun; 103(?):21-5. doi: NULL. [PMID: 10622039]
M F Para, P Meehan, J Holden-Wiltse, M Fischl, G Morse, R Shafer, L M Demeter, K Wood, T Nevin, N Virani-Ketter, W W Freimuth. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrobial agents and chemotherapy. 1999 Jun; 43(6):1373-8. doi: 10.1128/aac.43.6.1373. [PMID: 10348755]
O Hnatyszyn, A Broussalis, G Herrera, L Muschietti, J Coussio, V Martino, G Ferraro, M Font, A Monge, J J Martínez-Irujo, M Sanromán, M T Cuevas, E Santiago, J J Lasarte. Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. Phytotherapy research : PTR. 1999 May; 13(3):206-9. doi: 10.1002/(sici)1099-1573(199905)13:3<206::aid-ptr409>3.0.co;2-d. [PMID: 10353158]
A I Veldkamp, R P van Heeswijk, R M Hoetelmans, P L Meenhorst, J W Mulder, J M Lange, J H Beijnen. Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications. 1999 Apr; 727(1-2):151-7. doi: 10.1016/s0378-4347(99)00081-x. [PMID: 10360434]
K A Koeplinger, T J Raub, G E Padbury, Z Zhao. Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium. Journal of pharmaceutical and biomedical analysis. 1999 Mar; 19(3-4):399-411. doi: 10.1016/s0731-7085(98)00143-5. [PMID: 10704105]
P C Bellman. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS (London, England). 1998 Jul; 12(11):1333-40. doi: 10.1097/00002030-199811000-00015. [PMID: 9708413]
E De Clercq. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral research. 1998 Jun; 38(3):153-79. doi: 10.1016/s0166-3542(98)00025-4. [PMID: 9754886]
M T Borin, S R Cox, B D Herman, B J Carel, R D Anderson, W W Freimuth. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrobial agents and chemotherapy. 1997 Sep; 41(9):1892-7. doi: 10.1128/aac.41.9.1892. [PMID: 9303380]
M Chang, V K Sood, G J Wilson, D A Kloosterman, P E Sanders, M J Hauer, W Zhang, D G Branstetter. Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice. Drug metabolism and disposition: the biological fate of chemicals. 1997 Jul; 25(7):828-39. doi: NULL. [PMID: 9224777]
M Chang, V K Sood, D A Kloosterman, M J Hauer, P E Fagerness, P E Sanders, J J Vrbanac. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys. Drug metabolism and disposition: the biological fate of chemicals. 1997 Jul; 25(7):814-27. doi: NULL. [PMID: 9224776]
M T Borin, J H Chambers, B J Carel, W W Freimuth, S Aksentijevich, A A Piergies. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral research. 1997 Jun; 35(1):53-63. doi: 10.1016/s0166-3542(97)00011-9. [PMID: 9224961]
M T Borin, J H Chambers, B J Carel, S Gagnon, W W Freimuth. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clinical pharmacology and therapeutics. 1997 May; 61(5):544-53. doi: 10.1016/s0009-9236(97)90134-x. [PMID: 9164416]
C L Cheng, D E Smith, P L Carver, S R Cox, P B Watkins, D S Blake, C A Kauffman, K M Meyer, G L Amidon, P L Stetson. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clinical pharmacology and therapeutics. 1997 May; 61(5):531-43. doi: 10.1016/s0009-9236(97)90133-8. [PMID: 9164415]
S M Poppe, D E Slade, K T Chong, R R Hinshaw, P J Pagano, M Markowitz, D D Ho, H Mo, R R Gorman, T J Dueweke, S Thaisrivongs, W G Tarpley. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrobial agents and chemotherapy. 1997 May; 41(5):1058-63. doi: 10.1128/aac.41.5.1058. [PMID: 9145869]
M Chang, V K Sood, G J Wilson, D A Kloosterman, P E Sanders, M J Hauer, P E Fagerness. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug metabolism and disposition: the biological fate of chemicals. 1997 Feb; 25(2):228-42. doi: . [PMID: 9029054]
G D Morse, M A Fischl, M J Shelton, S R Cox, M Driver, M DeRemer, W W Freimuth. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrobial agents and chemotherapy. 1997 Jan; 41(1):169-74. doi: 10.1128/aac.41.1.169. [PMID: 8980774]
A J Chaput, R D'Ambrosio, G D Morse. In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral research. 1996 Oct; 32(2):81-9. doi: 10.1016/0166-3542(95)00984-1. [PMID: 8891167]
J Balzarini, H Pelemans, S Aquaro, C F Perno, M Witvrouw, D Schols, E De Clercq, A Karlsson. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Molecular pharmacology. 1996 Aug; 50(2):394-401. doi: NULL. [PMID: 8700148]
R T Davey, D G Chaitt, G F Reed, W W Freimuth, B R Herpin, J A Metcalf, P S Eastman, J Falloon, J A Kovacs, M A Polis, R E Walker, H Masur, J Boyle, S Coleman, S R Cox, L Wathen, C L Daenzer, H C Lane. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial agents and chemotherapy. 1996 Jul; 40(7):1657-64. doi: 10.1128/aac.40.7.1657. [PMID: 8807058]
W W Freimuth. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Advances in experimental medicine and biology. 1996; 394(?):279-89. doi: 10.1007/978-1-4757-9209-6_25. [PMID: 8815692]
B A Staton, M G Johnson, J M Friis, W J Adams. Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. Journal of chromatography. B, Biomedical applications. 1995 Jun; 668(1):99-106. doi: 10.1016/0378-4347(95)00045-k. [PMID: 7550987]